DOT1L and leukemia: A small molecule inhibitor of Dot1L (EPZ-5676 or pinometostat) has been developed by Epizyme, Inc. and is being studied in early clinical trials in both adult and pediatric patients with MLL-r leukemias (NCT01684150 and NCT02141828).